Dr. Dr. Daniel T. Michaeli

MD PhD MSc MSc BSc 👨‍⚕️💊💉🚀

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

New cancer drugs offer marginal survival benefit. Initial drug approvals with nonrobust trials may overstate efficacy. @US_FDA, physicians, patients, insurers must evaluate drug's efficacy, price, reimbursement on indication-specific level @JCO_ASCO
@ASCO https://t.co/mjVWOolKHb

[OncoDaily @oncodaily]

How could patients and payers save $3 billion on cancer drugs? - @DTMichaeli

https://t.co/8yisl58HAV

#Cancer #CancerDrugs #AccessToMedicines #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

[Dario Trapani @darioT_]

Findin' a best pricing approach 💲to #cancer drugs 💊💉 is still a challenge. Just after the presentation of the data at #ESMO24, @DTMichaeli 's full paper on #value -based pricing is now finally out!

Don't miss Daniel's work at: https://t.co/dRleFS9sht

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

💊💲New paper: "Value-Based Indication-Specific and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs"

🚨 Indication-specific/ weighted-average pricing could save 11% of US cancer drug expenditure

📖https://t.co/ypttcnI8BJ

@NCT_HD @uniklinik_hd @DKFZ

[Senology @Senology]

#Reviews: Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price https://t.co/QVcnFuEQzo - Breast Cancer - #senology #oncology #breast #cancer

[CancerTherapyAdvisor @CancerTherAdvsr]

Implementing weighted-average drug pricing in the United States could reduce the cost of cancer drugs, data suggest. Presented at #ESMO2024 by @DTMichaeli. #ESMO24 https://t.co/wTA23WRXqT

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

🫁 Our poster on new NSCLC drugs with @ADesaiMD at #ESMO24

💊56 FDA NSCLC approvals 2000-2022
🆙Avg. benefit: OS 3 mts, PFS 1.8 mts
🧬Biomarkers (64%) with shorter dvlp times, greater benefit, and cost-effectiveness

@NCT_HD @DKFZ @uniklinik_hd @LMU_Uniklinikum @ONealCancerUAB

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

💊 Excited to present our poster on the tumor response of cancer drugs in single-arm FDA approval trials with @MOSSIALOS at #ESMO24

🚀 Average ORR of 47% with a DoR of 11 months!

@NCT_HD @DKFZ @UniHeidelberg @uniklinik_hd @LMU_Uniklinikum @LSEHealthPolicy @myESMO

[Ash Paul @pash22]

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 @US_FDA approvals of cancer drugs and indications https://t.co/QzHLoaouRQ via @DTMichaeli et al

[BMJ Evidence-Based Medicine @BMJ_EBM]

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications

Original research by @DTMichaeli @NCT_HD @Uniklinik_HD @DKFZ et al.

Link: https://t.co/F0C5tqdV38

[BMJ Evidence-Based Medicine @BMJ_EBM]

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications

Original research by @DTMichaeli @NCT_HD @Uniklinik_HD @DKFZ et al.

Link: https://t.co/F0C5tqdV38

[BMJ Evidence-Based Medicine @BMJ_EBM]

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications

Original research by @DTMichaeli @NCT_HD @Uniklinik_HD @DKFZ et al.

Link: https://t.co/F0C5tqdV38

[JNCI @JNCI_Now]

Study reports cancer drugs with multiple FDA designations are associated with faster development but lack robust trial evidence and tend towards higher prices. @DTMichaeli @uniklinik_hd @NCT_HD @LMU_Muenchen @TU_Muenchen

Read here: https://t.co/mAQTDxex5z

[OncoDaily @oncodaily]

Our new article ‘Clinical trial design and treatment effects’ - @DTMichaeli
@bmj_company @LMU_Uniklinikum @oncodaily

#BMJ #Cancer #DrugSafety #FDA #OncoDaily #Oncology

https://t.co/94nXEltmAw

[OncoDaily @oncodaily]

Excited to share our latest poster from ESMOBreast24 on new breast cancer drugs - @DTMichaeli
@darioT_

#Cancer #ESMOBreast24 #OncoDaily #Oncology #CancerCare

https://t.co/413ZWIoThM

[Isabel Lorenzo @Isabelalor2015]

Pivotal trial design is significantly associated with measured treatment effects.
The analysed efficacy population (intention-to-treat, per-protocol, or as-treated) was not consistently associated with treatment effects. 🤷🏽‍♀️
#Meta-analysis https://t.co/0GTNvu9Lch

[Florian Naudet @NaudetFlorian]

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications @BMJ_EBM
https://t.co/yOKRLCPHj9

[Ash Paul @pash22]

Breast cancer drugs: @US_FDA approval, development time, efficacy, clinical benefits, innovative essays, trials, endpoints & price via @darioT_ & @DTMichaeli et al Conclusions are not very flattering @Liz_ORiordan @DrMarkLythgoe

[Ash Paul @pash22]

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 @US_FDA approvals of cancer drugs and indications https://t.co/DTgrFUeil2 via @DTMichaeli et al @DrMarkLythgoe

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

💊 Check our poster on breast cancer drugs at #ESMOBreast24

@darioT_ @csoncol @NCT_HD @DKFZ @uniklinik_hd @UniHeidelberg @myESMO

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

⚖️In conclusion, the Breakthrough Therapy Designation expedites patient access to innovative and effective, yet also expensive, new drugs. We find evidence that breakthrough drugs could offer patients a greater clinical benefit.

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

💥Breakthrough cancer drugs with @US_FDA approval: development time, innovation, trials, clinical benefit, epidemiology, and price - in @JNCCN @NCCN

📖 https://t.co/vQ46T6SoC3

@DKFZ @NCT_HD @uniklinik_hd @UniHeidelberg @Uni_Wuppertal

[Dr. Dr. Daniel T. Michaeli @DTMichaeli]

💲Price: BTD relative to non BTD drugs were sold for a substantially higher monthly price (USD 39,000 v 23,000).